

Rossella E Nappi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4893300/publications.pdf>

Version: 2024-02-01

297
papers

13,897
citations

18482
62
h-index

29157
104
g-index

319
all docs

319
docs citations

319
times ranked

8590
citing authors

#	ARTICLE	IF	CITATIONS
1	Expression and neuropeptidergic characterization of estrogen receptors (ER α and ER β) throughout the rat brain: Anatomical evidence of distinct roles of each subtype. <i>Journal of Neurobiology</i> , 1998, 36, 357-378.	3.6	525
2	Understanding weight gain at menopause. <i>Climacteric</i> , 2012, 15, 419-429.	2.4	430
3	Vaginal Health: Insights, Views & Attitudes (VIVA) – results from an international survey. <i>Climacteric</i> , 2012, 15, 36-44.	2.4	343
4	Circulating Levels of Allopregnanolone in Humans: Gender, Age, and Endocrine Influences. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2099-2103.	3.6	332
5	Sexual Dysfunction is Common in Women with Lower Urinary Tract Symptoms and Urinary Incontinence: Results of a Cross-Sectional Study. <i>European Urology</i> , 2004, 45, 642-648.	1.9	316
6	Course of Migraine During Pregnancy and Postpartum: A Prospective Study. <i>Cephalalgia</i> , 2003, 23, 197-205.	3.9	296
7	A 12-week treatment with fractional CO ₂ laser for vulvovaginal atrophy: a pilot study. <i>Climacteric</i> , 2014, 17, 363-369.	2.4	264
8	Women's voices in the menopause: Results from an international survey on vaginal atrophy. <i>Maturitas</i> , 2010, 67, 233-238.	2.4	249
9	Menopause and sexuality: Prevalence of symptoms and impact on quality of life. <i>Maturitas</i> , 2009, 63, 138-141.	2.4	229
10	Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. <i>Climacteric</i> , 2014, 17, 3-9.	2.4	211
11	Menstrual cycle-related changes in plasma oxytocin are relevant to normal sexual function in healthy women. <i>Hormones and Behavior</i> , 2005, 47, 164-169.	2.1	197
12	Female sexual dysfunction (FSD): Prevalence and impact on quality of life (QoL). <i>Maturitas</i> , 2016, 94, 87-91.	2.4	194
13	Serum Allopregnanolone Levels in Pregnant Women: Changes during Pregnancy, at Delivery, and in Hypertensive Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 2429-2433.	3.6	193
14	Immune challenge and immobilization stress induce transcription of the gene encoding the CRF receptor in selective nuclei of the rat hypothalamus. <i>Journal of Neuroscience</i> , 1995, 15, 2680-2695.	3.6	192
15	Sexual function after fractional microablative CO ₂ laser in women with vulvovaginal atrophy. <i>Climacteric</i> , 2015, 18, 219-225.	2.4	190
16	Characteristics of Menstrual and Nonmenstrual Attacks in Women with Menstrually Related Migraine Referred to Headache Centres. <i>Cephalalgia</i> , 2004, 24, 707-716.	3.9	188
17	Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. <i>International Journal of Women's Health</i> , 2013, 5, 437.	2.6	180
18	Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey. <i>Climacteric</i> , 2016, 19, 188-197.	2.4	157

#	ARTICLE	IF	CITATIONS
19	Vaginal health in the United States. Menopause, 2013, 20, 1043-1048.	2.0	152
20	Bone mass and long-term monophasic oral contraceptive treatment in young women. Contraception, 1995, 51, 221-224.	1.5	146
21	Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2695-e2709.	3.6	140
22	Memory Functioning at Menopause: Impact of Age in Ovariectomized Women. Gynecologic and Obstetric Investigation, 1999, 47, 29-36.	1.6	136
23	Low-level exposure to methylmercury modifies muscarinic cholinergic receptor binding characteristics in rat brain and lymphocytes: physiologic implications and new opportunities in biologic monitoring.. Environmental Health Perspectives, 2000, 108, 29-33.	6.0	131
24	Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). Journal of Headache and Pain, 2017, 18, 108.	6.0	130
25	Use of the Italian translation of the Female Sexual Function Index (FSFI) in routine gynecological practice. Gynecological Endocrinology, 2008, 24, 214-219.	1.7	125
26	Sexual Function and Endocrine Profile in Fertile Women With Type 1 Diabetes. Diabetes Care, 2006, 29, 312-316.	8.6	122
27	Premature ovarian insufficiency: an International Menopause Society White Paper. Climacteric, 2020, 23, 426-446.	2.4	121
28	Efficacy of <i>Cimicifuga racemosa</i> on climacteric complaints: A randomized study versus low-dose transdermal estradiol. Gynecological Endocrinology, 2005, 20, 30-35.	1.7	120
29	The CLOSER (Clarifying Vaginal Atrophy's Impact on Sex and Relationships (CLOSER) survey. Menopause, 2014, 21, 137-142.	0.6	118
30	ORIGINAL RESEARCH—PATHOPHYSIOLOGY: Clinical Biologic Pathophysiology of Women's Sexual Dysfunction. Journal of Sexual Medicine, 2005, 2, 4-25.	0.6	114
31	Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: A randomised, placebo-controlled, phase III trial. Maturitas, 2014, 78, 91-98.	2.4	113
32	Update on management of genitourinary syndrome of menopause: A practical guide. Maturitas, 2015, 82, 308-313.	2.4	111
33	Women's sexual dysfunction: a pathophysiological review. BJU International, 2004, 93, 1156-1164.	2.5	107
34	Clarifying Vaginal Atrophy's Impact on Sex and Relationships (CLOSER) survey. Menopause, 2014, 21, 137-142.	2.0	106
35	The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review. Menopause, 2018, 25, 837-847.	2.0	105
36	Migraine is a Risk Factor for Hypertensive Disorders in Pregnancy: A Prospective Cohort Study. Cephalalgia, 2009, 29, 286-292.	3.9	104

#	ARTICLE	IF	CITATIONS
37	Physiology of Female Sexual Function: Animal Models. <i>Journal of Sexual Medicine</i> , 2004, 1, 237-253.	0.6	100
38	The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. <i>Climacteric</i> , 2018, 21, 286-291.	2.4	100
39	Serum allopregnanolone in women with postpartum "blues". <i>Obstetrics and Gynecology</i> , 2001, 97, 77-80.	2.4	97
40	Effects of Surgical and Adjuvant Therapies for Breast Cancer on Sexuality, Cognitive Functions, and Body Weight. <i>Journal of Sexual Medicine</i> , 2010, 7, 1891-1900.	0.6	96
41	Course of primary headaches during hormone replacement therapy. <i>Maturitas</i> , 2001, 38, 157-163.	2.4	93
42	Female Urinary Incontinence During Intercourse: A Review on an Understudied Problem for Women's Sexuality. <i>Journal of Sexual Medicine</i> , 2009, 6, 40-48.	0.6	93
43	Continuing Medical Education: The Use of Estrogen Therapy in Women's Sexual Functioning (CME). <i>Journal of Sexual Medicine</i> , 2009, 6, 603-616.	0.6	93
44	Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women. <i>Frontiers in Endocrinology</i> , 2019, 10, 561.	3.5	90
45	The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI. <i>Climacteric</i> , 2012, 15, 267-274.	2.4	89
46	Sexual well-being after menopause: An International Menopause Society White Paper. <i>Climacteric</i> , 2018, 21, 415-427.	2.4	89
47	Aging is associated with changes in allopregnanolone concentrations in brain, endocrine glands and serum in male rats. <i>European Journal of Endocrinology</i> , 1998, 138, 316-321.	3.7	88
48	Endocrine Aspects of Women's Sexual Function. <i>Journal of Sexual Medicine</i> , 2010, 7, 561-585.	0.6	85
49	Mutation analysis of two candidate genes for premature ovarian failure, DACH2 and POF1B. <i>Human Reproduction</i> , 2004, 19, 2759-2766.	0.9	82
50	Women's perception of sexuality around the menopause: Outcomes of a European telephone survey. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2008, 137, 10-16.	1.1	82
51	Vasomotor symptoms in menopause: a biomarker of cardiovascular disease risk and other chronic diseases?. <i>Climacteric</i> , 2017, 20, 306-312.	2.4	80
52	Fundamental Concepts and Novel Aspects of Polycystic Ovarian Syndrome: Expert Consensus Resolutions. <i>Frontiers in Endocrinology</i> , 2020, 11, 516.	3.5	76
53	Reproductive depression. <i>Gynecological Endocrinology</i> , 2012, 28, 42-45.	1.7	74
54	The burden of vulvovaginal atrophy on women's daily living: implications on quality of life from a face-to-face real-life survey. <i>Menopause</i> , 2019, 26, 485-491.	2.0	72

#	ARTICLE	IF	CITATIONS
55	Diaries and Calendars for Migraine. A Review. Cephalalgia, 2006, 26, 905-916.	3.9	71
56	Serum Allopregnanolone in Women With Postpartum "Blues". Obstetrics and Gynecology, 2001, 97, 77-80.	2.4	70
57	Hormone Supplementation Differently Affects Migraine in Postmenopausal Women. Headache, 2002, 42, 924-929.	3.9	69
58	Female Sexual Dysfunction"Medical and Psychological Treatments, Committee 14. Journal of Sexual Medicine, 2017, 14, 1463-1491.	0.6	69
59	Influence of the Estrous Cycle on c-fos and CRH Gene Transcription in the Brain of Endotoxin-Challenged Female Rats. Neuroendocrinology, 1997, 65, 29-46.	2.5	66
60	New attitudes to sexuality in the menopause: clinical evaluation and diagnosis. Climacteric, 2007, 10, 105-108.	2.4	66
61	Effects of an estrogen-free, desogestrel-containing oral contraceptive in women with migraine with aura: a prospective diary-based pilot study. Contraception, 2011, 83, 223-228.	1.5	66
62	Therapeutic options for postmenopausal female sexual dysfunction. Climacteric, 2010, 13, 103-120.	2.4	65
63	Impact of intravesical hyaluronic acid and chondroitin sulfate on bladder pain syndrome/interstitial cystitis. International Urogynecology Journal, 2012, 23, 1193-1199.	1.4	64
64	Couplepause: A New Paradigm in Treating Sexual Dysfunction During Menopause and Andropause. Sexual Medicine Reviews, 2018, 6, 384-395.	2.9	64
65	Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH). Journal of Headache and Pain, 2018, 19, 76.	6.0	64
66	Menopause: a cardiometabolic transition. Lancet Diabetes and Endocrinology, 2022, 10, 442-456.	11.4	64
67	Interstitial Cystitis is Associated with Vulvodynia and Sexual Dysfunction" A Case-Control Study. Journal of Sexual Medicine, 2011, 8, 1726-1734.	0.6	63
68	Evidence for a role of neurosteroids in modulation of diurnal changes and acute stress-induced corticosterone secretion in rats. Gynecological Endocrinology, 1995, 9, 1-7.	1.7	62
69	Hormonal and psycho-relational aspects of sexual function during menopausal transition and at early menopause. Maturitas, 2010, 67, 78-83.	2.4	62
70	The CLOSER survey: Impact of postmenopausal vaginal discomfort on relationships between women and their partners in Northern and Southern Europe. Maturitas, 2013, 75, 373-379.	2.4	62
71	Changes in Nociceptive Flexion Reflex Threshold Across the Menstrual Cycle in Healthy Women. Psychosomatic Medicine, 2002, 64, 621-626.	2.0	60
72	Menstrual Cycle-Related Changes in Circulating Androgens in Healthy Women With Self-Reported Normal Sexual Function. Journal of Sexual Medicine, 2008, 5, 854-863.	0.6	59

#	ARTICLE	IF	CITATIONS
73	Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials. <i>Gynecological Endocrinology</i> , 2010, 26, 804-814.	1.7	59
74	SARS-CoV-2, testosterone and frailty in males (PROTEGGIMI): A multidimensional research project. <i>Andrology</i> , 2021, 9, 19-22.	3.5	59
75	Advances in pharmacotherapy for treating female sexual dysfunction. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 875-887.	1.8	57
76	Genitourinary Syndrome of Menopause in Breast Cancer Survivors: Are We Facing New and Safe Hopes?. <i>Clinical Breast Cancer</i> , 2015, 15, 413-420.	2.4	57
77	Ovulatory cycle influences the stimulatory effect of stress on the expression of corticotropin-releasing factor receptor messenger ribonucleic acid in the paraventricular nucleus of the female rat hypothalamus.. <i>Endocrinology</i> , 1995, 136, 4073-4083.	2.8	55
78	Menopause hormone replacement therapy and cancer risk: an Italian record linkage investigation. <i>Annals of Oncology</i> , 2008, 19, 150-155.	1.2	55
79	Thyroidal effect of metformin treatment in patients with polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2011, 75, 378-381.	2.4	55
80	Effect of Immune and Metabolic Challenges on the Luteinizing Hormone-Releasing Hormone Neuronal System in Cycling Female Rats: An Evaluation at the Transcriptional Level*. <i>Endocrinology</i> , 1997, 138, 1374-1384.	2.8	54
81	Change to Either a Nonandrogenic or Androgenic Progestin-Containing Oral Contraceptive Preparation is Associated with Improved Sexual Function in Women with Oral Contraceptive-Associated Sexual Dysfunction. <i>Journal of Sexual Medicine</i> , 2013, 10, 3069-3079.	0.6	53
82	Electrical Stimulation (ES) in the Management of Sexual Pain Disorders. <i>Journal of Sex and Marital Therapy</i> , 2003, 29, 103-110.	1.5	52
83	Effect of a contraceptive pill containing estradiol valerate and dienogest (E2V/DNG) in women with menstrually-related migraine (MRM). <i>Contraception</i> , 2013, 88, 369-375.	1.5	52
84	Self-Reported Sexual Symptoms in Women Attending Menopause Clinics. <i>Gynecologic and Obstetric Investigation</i> , 2002, 53, 181-187.	1.6	50
85	PCOS, Sexuality, and Clitoral Vascularisation: A Pilot Study. <i>Journal of Sexual Medicine</i> , 2008, 5, 2886-2894.	0.6	49
86	The brain as a target organ of gonadal steroids. <i>Psychoneuroendocrinology</i> , 1992, 17, 385-390.	2.7	48
87	Stress-Induced Genetic Expression of a Selective Corticotropin-Releasing Factor-Receptor Subtype Within the Rat Ovaries: An Effect Dependent on the Ovulatory Cycle1. <i>Biology of Reproduction</i> , 1995, 53, 1417-1428.	2.7	48
88	Attitudes, perceptions and knowledge about the vagina: the International Vagina Dialogue Survey. <i>Contraception</i> , 2006, 73, 493-500.	1.5	48
89	Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden. <i>Menopause</i> , 2021, 28, 875-882.	2.0	48
90	Hormonal contraception in women with migraine: is progestogen-only contraception a better choice?. <i>Journal of Headache and Pain</i> , 2013, 14, 66.	6.0	47

#	ARTICLE	IF	CITATIONS
91	The REVIVE (REal Women's Views of Treatment Options for Menopausal Vaginal ChangEs) survey in Europe: Country-specific comparisons of postmenopausal women's perceptions, experiences and needs. <i>Maturitas</i> , 2016, 91, 81-90.	2.4	47
92	Serum Allopregnanolone Levels in Pregnant Women: Changes during Pregnancy, at Delivery, and in Hypertensive Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 2429-2433.	3.6	46
93	Hypothalamic amenorrhea: evidence for a central derangement of hypothalamic-pituitary-adrenal cortex axis activity. <i>Fertility and Sterility</i> , 1993, 59, 571-576.	1.0	45
94	Insight into Urogynecologic Features of Women with Interstitial Cystitis/Painful Bladder Syndrome. <i>European Urology</i> , 2008, 54, 1145-1153.	1.9	45
95	Hormonal Contraception and Female Sexuality: Position Statements from the European Society of Sexual Medicine (ESSM). <i>Journal of Sexual Medicine</i> , 2019, 16, 1681-1695.	0.6	45
96	Insomnia and menopause: a narrative review on mechanisms and treatments. <i>Climacteric</i> , 2020, 23, 539-549.	2.4	45
97	Clitoral circulation in postmenopausal women with sexual dysfunction: A pilot randomized study with hormone therapy. <i>Maturitas</i> , 2006, 55, 288-295.	2.4	43
98	Validation of the McCoy Female Sexuality Questionnaire in an Italian Sample. <i>Archives of Sexual Behavior</i> , 2005, 34, 641-647.	1.9	42
99	Hypoactive sexual desire disorder in postmenopausal women. <i>Gynecological Endocrinology</i> , 2006, 22, 318-323.	1.7	42
100	Extended regimen combined oral contraception: A review of evolving concepts and acceptance by women and clinicians. <i>European Journal of Contraception and Reproductive Health Care</i> , 2016, 21, 106-115.	1.5	41
101	Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women. <i>Maturitas</i> , 2019, 124, 55-61.	2.4	41
102	Is transrectal ultrasonography a reliable diagnostic approach in ejaculatory duct sub-obstruction?. <i>Human Reproduction</i> , 1997, 12, 2186-2191.	0.9	40
103	Menstrual Cycle-Related Morphometric and Vascular Modifications of the Clitoris. <i>Journal of Sexual Medicine</i> , 2008, 5, 2853-2861.	0.6	40
104	The Impact of the Mid-Urethral Slings for the Treatment of Stress Urinary Incontinence on Female Sexuality. <i>Journal of Sexual Medicine</i> , 2009, 6, 1534-1542.	0.6	40
105	The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy. <i>Climacteric</i> , 2015, 18, 233-240.	2.4	40
106	International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. <i>Journal of Sexual Medicine</i> , 2021, 18, 849-867.	0.6	40
107	The effects of oestrogen on urogenital health. <i>Maturitas</i> , 2009, 63, 149-151.	2.4	39
108	Effect of Sex and Estrogens on Neuronal Activation in an Animal Model of Migraine. <i>Headache</i> , 2013, 53, 288-296.	3.9	39

#	ARTICLE	IF	CITATIONS
109	Use of and attitudes towards emergency contraception: A survey of women in five European countries. <i>European Journal of Contraception and Reproductive Health Care</i> , 2014, 19, 93-101.	1.5	39
110	Oral D-mannose in recurrent urinary tract infections in women: a pilot study. <i>Journal of Clinical Urology</i> , 2014, 7, 208-213.	0.1	39
111	Perineal floor efficiency in sexually potent and impotent men. <i>International Journal of Impotence Research</i> , 1999, 11, 153-157.	1.8	38
112	Uterine myoma in postmenopause: a comparison between two therapeutic schedules of HRT. <i>Maturitas</i> , 2000, 37, 27-32.	2.4	38
113	Validation of the Sexual Interest and Desire Inventory-Female in Hypoactive Sexual Desire Disorder. <i>Journal of Sexual Medicine</i> , 2010, 7, 3918-3928.	0.6	37
114	Headache and adverse pregnancy outcomes: a prospective study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2012, 161, 140-143.	1.1	37
115	Stimulating Effect of HIV-1 Coat Protein gp120 on Corticotropin-Releasing Hormone and Arginine Vasopressin in the Rat Hypothalamus: Involvement of Nitric Oxide. <i>Experimental Neurology</i> , 2000, 166, 376-384.	4.1	36
116	Sexuality in premature ovarian insufficiency. <i>Climacteric</i> , 2019, 22, 289-295.	2.4	36
117	Estradiol supplementation modulates neuroendocrine response to M-chlorophenylpiperazine in menstrual status migrainosus triggered by oral contraception-free interval. <i>Human Reproduction</i> , 2005, 20, 3423-3428.	0.9	35
118	Markers of local immunity in cervico-vaginal secretions of HIV infected women: implications for HIV shedding. <i>Sexually Transmitted Infections</i> , 2004, 80, 108-112.	1.9	34
119	Involvement of μ -opioid receptors in the modulation of pituitary-adrenal axis in normal and stressed rats. <i>Journal of Endocrinological Investigation</i> , 1995, 18, 1-7.	3.3	33
120	Nerve-Sparing Approach Reduces Sexual Dysfunction in Patients Undergoing Laparoscopic Radical Hysterectomy. <i>Journal of Sexual Medicine</i> , 2014, 11, 3012-3020.	0.6	33
121	Characteristics of post-menopausal women with genitourinary syndrome of menopause: Implications for vulvovaginal atrophy diagnosis and treatment selection. <i>Maturitas</i> , 2015, 81, 462-469.	2.4	33
122	Haemostatic and metabolic impact of estradiol pills and drospirenone-containing ethinylestradiol pills vs. levonorgestrel-containing ethinylestradiol pills: A literature review. <i>European Journal of Contraception and Reproductive Health Care</i> , 2015, 20, 329-343.	1.5	31
123	Sexual dysfunction in obese women: Does obstructive sleep apnea play a role?. <i>Sleep Medicine</i> , 2013, 14, 252-256.	1.6	30
124	Attitudes and perceptions towards vulvar and vaginal atrophy in Italian post-menopausal women: Evidence from the European REVIVE survey. <i>Maturitas</i> , 2016, 91, 74-80.	2.4	30
125	Diagnosis and management of symptoms associated with vulvovaginal atrophy: expert opinion on behalf of the Italian VVA study group. <i>Gynecological Endocrinology</i> , 2016, 32, 602-606.	1.7	30
126	Effect of chronic intermittent stress on rat pregnancy and postnatal development. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 1993, 51, 41-45.	1.1	29

#	ARTICLE	IF	CITATIONS
127	Different effects of tibolone and low-dose EPT in the management of postmenopausal women with primary headaches. <i>Menopause</i> , 2006, 13, 818-825.	2.0	29
128	Cigarette Smoking Decreases the Genital Vascularization in Young Healthy, Eumenorrheic Women. <i>Journal of Sexual Medicine</i> , 2011, 8, 1717-1725.	0.6	29
129	Headaches During Pregnancy. <i>Current Pain and Headache Reports</i> , 2011, 15, 289-294.	2.9	28
130	Incidence of genitourinary conditions in women with a diagnosis of vulvar/vaginal atrophy. <i>Current Medical Research and Opinion</i> , 2014, 30, 143-148.	1.9	28
131	Role of Estrogens in Menstrual Migraine. <i>Cells</i> , 2022, 11, 1355.	4.1	28
132	3-D Volumetric and Vascular Analysis of the Urethrovaginal Space in Young Women With or Without Vaginal Orgasm. <i>Journal of Sexual Medicine</i> , 2010, 7, 1445-1453.	0.6	26
133	Sexual Function and Distress in Women Treated for Primary Headaches in a Tertiary University Center. <i>Journal of Sexual Medicine</i> , 2012, 9, 761-769.	0.6	26
134	In-vitro culture system for mesenchymal progenitor cells derived from waste human ovarian follicular fluid. <i>Reproductive BioMedicine Online</i> , 2014, 29, 457-469.	2.4	25
135	Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy. <i>Climacteric</i> , 2016, 19, 60-65.	2.4	25
136	Missed pills: frequency, reasons, consequences and solutions. <i>European Journal of Contraception and Reproductive Health Care</i> , 2017, 22, 165-169.	1.5	25
137	Migraine, low-dose combined hormonal contraceptives, and ischemic stroke in young women: a systematic review and suggestions for future research. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 313-317.	2.8	25
138	Acute stress- or lipopolysaccharide-induced corticosterone secretion in female rats is independent of the oestrous cycle. <i>European Journal of Endocrinology</i> , 1994, 131, 535-539.	3.7	24
139	Management of hypoactive sexual desire disorder in women: current and emerging therapies. <i>International Journal of Women's Health</i> , 2010, 2, 167.	2.6	24
140	Menopause and sexual desire: the role of testosterone. <i>Menopause International</i> , 2010, 16, 162-168.	1.6	24
141	Validity of the Decreased Sexual Desire Screener for Diagnosing Hypoactive Sexual Desire Disorder. <i>Journal of Sex and Marital Therapy</i> , 2013, 39, 132-143.	1.5	24
142	Differences in sexual desire between women with clinical versus biochemical signs of hyperandrogenism in polycystic ovarian syndrome. <i>Hormones and Behavior</i> , 2013, 63, 65-71.	2.1	24
143	Serum Allopregnanolone Levels Relate to FSFI Score During the Menstrual Cycle. <i>Journal of Sex and Marital Therapy</i> , 2003, 29, 95-102.	1.5	23
144	Cutoff Score of the Sexual Interest and Desire Inventory-Female for Diagnosis of Hypoactive Sexual Desire Disorder. <i>Journal of Women's Health</i> , 2010, 19, 2191-2195.	3.3	23

#	ARTICLE	IF	CITATIONS
145	Maintaining sexuality in menopause. Post Reproductive Health, 2014, 20, 22-29.	0.9	23
146	Anti-Mullerian hormone as a predictor of ovarian reserve in ART protocols: the hidden role of thyroid autoimmunity. Reproductive Biology and Endocrinology, 2015, 13, 106.	3.3	23
147	To be or not to be in sexual desire: the androgen dilemma. Climacteric, 2015, 18, 672-674.	2.4	23
148	Menopause transition: a golden age to prevent cardiovascular disease. Lancet Diabetes and Endocrinology, 2021, 9, 135-137.	11.4	23
149	Recent advances in understanding/management of premenstrual dysphoric disorder/premenstrual syndrome. Faculty Reviews, 2022, 11, 11.	3.9	23
150	Persistence with oral and transdermal hormone replacement therapy and hospitalisation for cardiovascular outcomes. Maturitas, 2007, 57, 315-324.	2.4	22
151	Migraine and reproductive life. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2010, 97, 303-322.	1.8	22
152	The CLOSER survey: Impact of postmenopausal vaginal discomfort on women and male partners in the UK. Menopause International, 2013, 19, 69-76.	1.6	22
153	Surgical treatment affects perceived stress differently in women with endometriosis: correlation with severity of pain. Fertility and Sterility, 2015, 103, 433-438.	1.0	22
154	International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. Journal of Women's Health, 2021, 30, 474-491.	3.3	22
155	Sumatriptan (50 mg tablets vs. 25 mg suppositories) in the acute treatment of menstrually related migraine and oral contraceptive-induced menstrual migraine: a pilot study. Gynecological Endocrinology, 2010, 26, 773-779.	1.7	21
156	Neuroendocrine aspects of migraine in women. Gynecological Endocrinology, 2012, 28, 37-41.	1.7	21
157	Secondary Provoked Vestibulodynia in Sexually Active Women with Uncomplicated Recurrent Urinary Tract Infections. Journal of Sexual Medicine, 2013, 10, 2265-2273.	0.6	21
158	HPV Infection Affects Human Sperm Functionality by Inhibition of Aquaporin-8. Cells, 2020, 9, 1241.	4.1	21
159	A core outcome set for vasomotor symptoms associated with menopause: the COMMA (Core Outcomes) Trial. BJOG, 2021, 128, 1078-1084.	1.1	21
160	Estrous cycle- and acute stress-related changes of rat ovarian immunoreactive corticotropin-releasing factor. Gynecological Endocrinology, 1996, 10, 75-82.	1.7	20
161	Psychoneuroendocrine correlates of secondary amenorrhea. Archives of Women's Mental Health, 2003, 6, 83-89.	2.6	20
162	Impaired Outcome of Controlled Ovarian Hyperstimulation in Women with Thyroid Autoimmune Disease. Thyroid, 2013, 23, 1312-1318.	4.5	20

#	ARTICLE	IF	CITATIONS
163	Effect of local estrogen therapy (LET) on urinary and sexual symptoms in premenopausal women with interstitial cystitis/bladder pain syndrome (IC/BPS). <i>Gynecological Endocrinology</i> , 2015, 31, 828-832.	1.7	20
164	Impact of vulvovaginal atrophy of menopause: prevalence and symptoms in Italian women according to the EVES study. <i>Gynecological Endocrinology</i> , 2019, 35, 453-459.	1.7	20
165	Oestrogen-free oral contraception with a 4â€‰mg drospirenone-only pill: new data and a review of the literature. <i>European Journal of Contraception and Reproductive Health Care</i> , 2020, 25, 221-227.	1.5	20
166	Microablative Fractional CO2 Laser for Vulvovaginal Atrophy in Women With a History of Breast Cancer: A Pilot Study at 4-week Follow-up. <i>Clinical Breast Cancer</i> , 2021, 21, e539-e546.	2.4	20
167	Hormonal management of migraine at menopause. <i>Menopause International</i> , 2009, 15, 82-86.	1.6	19
168	The Role of 3-D Ultrasonography in the Evaluation of Menstrual Cycle-Related Vascular Modifications of the Clitoris. A Prospective Pilot Study. <i>Journal of Sexual Medicine</i> , 2009, 6, 2715-2721.	0.6	19
169	LEI (Lack of tEstosterone Impact) survey in a clinical sample with surgical menopause. <i>Climacteric</i> , 2009, 12, 533-540.	2.4	19
170	PCOS and Urethrovaginal Space: 3-D Volumetric and Vascular Analysis. <i>Journal of Sexual Medicine</i> , 2010, 7, 2755-2764.	0.6	19
171	Modulation of nociceptive threshold by combined hormonal contraceptives in women with oestrogen-withdrawal migraine attacks: a pilot study. <i>Journal of Headache and Pain</i> , 2016, 17, 70.	6.0	19
172	Vaginal Health: Insights, Views & Attitudes (VIVA-LATAM): results from a survey in Latin America. <i>Climacteric</i> , 2018, 21, 397-403.	2.4	19
173	Non-hormonal strategies for managing menopausal symptoms in cancer survivors: an update. <i>Ecancermedalscience</i> , 2019, 13, 909.	1.1	19
174	A core outcome set for genitourinary symptoms associated with menopause: the COMMA (Core) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3	2.0	19
175	Neuroendocrine Response to the Serotonin Agonist M-Chlorophenylpiperazine in Women with Menstrual Status migrainosus. <i>Neuroendocrinology</i> , 2003, 78, 52-60.	2.5	18
176	Ultrasonographic and Doppler Findings of Subclinical Clitoral Microtraumatism in Mountain Bikers and Horseback Riders. <i>Journal of Sexual Medicine</i> , 2009, 6, 464-468.	0.6	18
177	Dietary intakes in infertile women a pilot study. <i>Nutrition Journal</i> , 2009, 8, 53.	3.4	18
178	Pharmacogenomics and sexuality: a vision. <i>Climacteric</i> , 2013, 16, 25-30.	2.4	18
179	Gender Differences at the Onset of Autoimmune Thyroid Diseases in Children and Adolescents. <i>Frontiers in Endocrinology</i> , 2020, 11, 229.	3.5	18
180	Transdermal Hormonal Therapy in Perimenstrual Migraine: Why, When and How?. <i>Current Pain and Headache Reports</i> , 2012, 16, 467-473.	2.9	17

#	ARTICLE	IF	CITATIONS
181	Women's preferences for menstrual bleeding frequency: results of the Inconvenience Due to Women's Monthly Bleeding (ISY) survey. <i>European Journal of Contraception and Reproductive Health Care</i> , 2016, 21, 242-250.	1.5	17
182	What women think about menopause: An Italian survey. <i>Maturitas</i> , 2021, 147, 47-52.	2.4	17
183	Vaginal Health: Insights, Views & Attitudes (VIVA) survey - Canadian cohort. <i>Menopause International</i> , 2013, 19, 20-27.	1.6	16
184	Noncontraceptive benefits of the estradiol valerate/dienogest combined oral contraceptive: a review of the literature. <i>International Journal of Women's Health</i> , 2014, 6, 711.	2.6	16
185	Effectiveness of hyaluronate-based pessaries in the treatment of vulvovaginal atrophy in postmenopausal women. <i>Climacteric</i> , 2020, 23, 519-524.	2.4	16
186	Efficacy and safety of a new vaginal gel for the treatment of symptoms associated with vulvovaginal atrophy in postmenopausal women: A double-blind randomized placebo-controlled study. <i>Maturitas</i> , 2021, 147, 34-40.	2.4	16
187	Effect of Immune and Metabolic Challenges on the Luteinizing Hormone-Releasing Hormone Neuronal System in Cycling Female Rats: An Evaluation at the Transcriptional Level. <i>Endocrinology</i> , 1997, 138, 1374-1384.	2.8	16
188	Effects of a Yeast-Based Dietary Supplementation on Premenstrual Syndrome. <i>Gynecologic and Obstetric Investigation</i> , 1997, 43, 120-124.	1.6	15
189	Eating disorders and Axis I psychiatric comorbidity in amenorrheic women. , 1998, 24, 137-146.		15
190	Clitoral Artery Blood Flow in Healthy Young Women: Preliminary Report on Menstrual Cycle and Hormonal Contraception. <i>Journal of Sex and Marital Therapy</i> , 2002, 28, 187-193.	1.5	15
191	Effects of combined hormonal contraception on health and wellbeing: Women's knowledge in northern Italy. <i>European Journal of Contraception and Reproductive Health Care</i> , 2015, 20, 36-46.	1.5	15
192	The European Vulvovaginal Epidemiological Survey (EVES): impact on sexual function of vulvovaginal atrophy of menopause. <i>Menopause</i> , 2020, 27, 423-429.	2.0	15
193	Moderate Alcohol Intake, Genital Vascularization, and Sexuality in Young, Healthy, Eumenorrheic Women. A Pilot Study. <i>Journal of Sexual Medicine</i> , 2011, 8, 2334-2343.	0.6	14
194	Robotic Single-Site Surgery for Female-to-Male Transsexuals: Preliminary Experience. <i>Scientific World Journal</i> , The, 2014, 2014, 1-4.	2.1	14
195	Efficacy, tolerability and safety of a new medical device, Monurelle Biogel Â® vaginal gel, in the treatment of vaginal dryness: a randomized clinical trial in women of reproductive age. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2016, 203, 82-88.	1.1	14
196	Women's preferences for menstrual bleeding frequency in 12 European countries: the Inconvenience Due to Women's Monthly Bleeding (ISY) survey. <i>European Journal of Contraception and Reproductive Health Care</i> , 2017, 22, 268-273.	1.5	14
197	The sexuological impact of hormonal contraceptives based on their route of administration. <i>Gynecological Endocrinology</i> , 2017, 33, 218-222.	1.7	13
198	Perspectives on counseling patients about menopausal hormone therapy: strategies in a complex data environment. <i>Menopause</i> , 2018, 25, 937-949.	2.0	13

#	ARTICLE	IF	CITATIONS
199	Real-world experience of women using extended-cycle vs monthly-cycle combined oral contraception in the United States: the National Health and Wellness Survey. <i>BMC Women's Health</i> , 2018, 18, 22.	2.0	13
200	Premenstrual dysphoric disorder and eating disorders. <i>Cephalalgia</i> , 1997, 17, 25-28.	3.9	12
201	Medical Treatment of Female Sexual Dysfunction. <i>Urologic Clinics of North America</i> , 2022, 49, 299-307.	1.8	12
202	Effect of naltrexone treatment on the treadmill exercise-induced hormone release in amenorrheic women. <i>Journal of Endocrinological Investigation</i> , 1992, 15, 839-847.	3.3	11
203	Adrenergic and serotonergic receptors mediate the immunological activation of corticosterone secretion in male rats. <i>Gynecological Endocrinology</i> , 1996, 10, 149-154.	1.7	11
204	Parkinson's disease and reproductive life events. <i>Neurological Sciences</i> , 2002, 23, s85-s86.	1.9	11
205	Toward a new concept of "natural balance" in oral estroprogestin contraception. <i>Gynecological Endocrinology</i> , 2013, 29, 891-896.	1.7	11
206	Why are there no FDA-approved treatments for female sexual dysfunction?. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1735-1738.	1.8	11
207	The neuroendocrine effects of sumatriptan, a specific ligand for 5-HT ₁ -like receptors. <i>Clinical Endocrinology</i> , 1994, 40, 211-214.	2.4	10
208	Periovarian Morphometric and Vascular Modifications of the Clitoris in Young Adult and Middle-Aged Women. A Pilot Study. <i>Journal of Sexual Medicine</i> , 2009, 6, 2707-2714.	0.6	10
209	The inconvenience due to women's monthly bleeding (ISY) survey: a study of premenstrual symptoms among 5728 women in Europe. <i>European Journal of Contraception and Reproductive Health Care</i> , 2017, 22, 354-359.	1.5	10
210	Monurelle Biogel [®] vaginal gel in the treatment of vaginal dryness in postmenopausal women. <i>Climacteric</i> , 2017, 20, 467-475.	2.4	10
211	Climacteric Complaints, Female Identity, and Sexual Dysfunctions. <i>Journal of Sex and Marital Therapy</i> , 2001, 27, 567-576.	1.5	9
212	Dietary underreporting in women affected by polycystic ovary syndrome: A pilot study. <i>Nutrition and Dietetics</i> , 2019, 76, 560-566.	1.8	9
213	Vulvovaginal atrophy (VVA) in breast cancer survivors (BCS) is still an unmet medical need: results of an Italian Delphi Panel. <i>Supportive Care in Cancer</i> , 2020, 28, 2507-2512.	2.2	9
214	The role of hormone therapy in urogenital health after menopause. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2021, 35, 101595.	4.7	9
215	Men with COVID-19 die. Women survive. <i>Maturitas</i> , 2022, 158, 34-36.	2.4	9
216	Counseling and management of patients requesting subcutaneous contraceptive implants: proposal for a decisional algorithm. <i>Gynecological Endocrinology</i> , 2014, 30, 525-531.	1.7	8

#	ARTICLE	IF	CITATIONS
217	Robotic Single Site Hysterectomy with Bilateral Salpingo-Oophorectomy in Female to Male Transsexualism. <i>Journal of Sexual Medicine</i> , 2014, 11, 313-313.	0.6	8
218	Clinical profile of women with vulvar and vaginal atrophy who are not candidates for local vaginal estrogen therapy. <i>Minerva Obstetrics and Gynecology</i> , 2017, 69, 370-380.	1.0	8
219	Menopause and female sexual dysfunctions. <i>Minerva Obstetrics and Gynecology</i> , 2022, 74, .	1.0	8
220	Corticotropin-releasing factor (CRF) and stress-related reproductive failure: The brain as a state of the art or the ovary as a novel clue?. <i>Journal of Endocrinological Investigation</i> , 1995, 18, 872-880.	3.3	7
221	Topiramate for migraine prevention in fertile women: Reproductive counseling is warranted. <i>Cephalalgia</i> , 2014, 34, 1097-1099.	3.9	7
222	Multinational, multicentre, randomised, open-label study evaluating the impact of a 91-day extended regimen combined oral contraceptive, compared with two 28-day traditional combined oral contraceptives, on haemostatic parameters in healthy women. <i>European Journal of Contraception and Reproductive Health Care</i> , 2014, 19, 285-294.	1.5	7
223	Development and conceptual validation of a questionnaire to help contraceptive choice: CHLOE (Contraception: HeLping for wOMen's choiceE). <i>European Journal of Contraception and Reproductive Health Care</i> , 2017, 22, 286-290.	1.5	7
224	Male perception about the inconveniences associated with monthly bleeding for their partner "an international survey. <i>European Journal of Contraception and Reproductive Health Care</i> , 2018, 23, 1-11.	1.5	7
225	What are the challenges in prescribing pharmacotherapy for female sexual dysfunctions?. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 777-779.	1.8	7
226	Viewing symptoms associated with Vulvovaginal Atrophy (VVA)/Genitourinary syndrome of menopause (GSM) through the estro-androgenic lens "Cluster analysis of a web-based Italian survey among women over 40. <i>Maturitas</i> , 2020, 140, 72-79.	2.4	7
227	The European Vulvovaginal Epidemiological Survey (EVES). Impact of history of breast cancer on prevalence, symptoms, sexual function and quality of life related to vulvovaginal atrophy. <i>Gynecological Endocrinology</i> , 2021, 37, 78-82.	1.7	7
228	The Gynogram: A Multicentric Validation of a New Psychometric Tool to Assess Coital Pain Associated With VVA and Its Impact on Sexual Quality of Life in Menopausal Women. <i>Journal of Sexual Medicine</i> , 2021, 18, 955-965.	0.6	7
229	Efficacy and safety of prolonged-release hyaluronic acid derivative vaginal application in the postpartum period: a prospective randomised clinical trial. <i>Annals of Medicine</i> , 2021, 53, 1589-1597.	3.8	7
230	Premenstrual Syndrome and Premenstrual Dysphoric Disorder as Centrally Based Disorders. <i>Endocrines</i> , 2022, 3, 127-138.	1.0	7
231	Provoked Vestibulodynia and Topical Treatment: A New Option. <i>Healthcare (Switzerland)</i> , 2022, 10, 830.	2.0	7
232	Bicuculline enhances the corticosterone secretion induced by lipopolysaccharide and interleukin-1 β in male rats. <i>Journal of Endocrinological Investigation</i> , 1996, 19, 83-87.	3.3	6
233	Genistein Supplements Might Not Induce Clitoral Modifications in Postmenopausal Women: A Prospective, Pilot Study. <i>Journal of Sexual Medicine</i> , 2009, 6, 3132-3138.	0.6	6
234	The American "European difference in vulvar and vaginal atrophy views: a lesson from the REVIVE Survey. <i>Climacteric</i> , 2016, 19, 252-255.	2.4	6

#	ARTICLE	IF	CITATIONS
235	Efficacy and tolerability of a spray formulation containing Visnadine in women self-reporting sexual symptoms: a randomized double-blind placebo-controlled pilot study. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 729-737.	3.3	6
236	Role of testosterone in feminine sexuality. <i>Journal of Endocrinological Investigation</i> , 2003, 26, 97-101.	3.3	6
237	Psychosexual well-being in women using oral contraceptives containing drospirenone. <i>Functional Neurology</i> , 2009, 24, 71-5.	1.3	6
238	Polycystic ovary syndrome and sexuality. <i>Gynecological Endocrinology</i> , 2022, 38, 535-536.	1.7	6
239	Italian position statement on hormone replacement therapy following the National Conference on Menopause and Hormone Replacement Therapy, Villa Tuscolana, Frascati (Rome), May 8-9, 2007. <i>Gynecological Endocrinology</i> , 2007, 23, 436-444.	1.7	5
240	Issues concerning the use of hormone replacement therapy and risk of fracture: a population-based, nested case-control study. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 123-129.	2.4	5
241	Counseling on vaginal delivery of contraceptive hormones: implications for women's body knowledge and sexual health. <i>Gynecological Endocrinology</i> , 2013, 29, 1015-1021.	1.7	5
242	Pharmacokinetic considerations for therapies used to treat interstitial cystitis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 673-684.	3.3	5
243	Diurnal Variation of Plasma Brain-Derived Neurotrophic Factor Levels in Women with Functional Hypothalamic Amenorrhea. <i>Neuroendocrinology</i> , 2015, 101, 256-262.	2.5	5
244	Testosterone for women: green light for sex, amber light for health?. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 738-739.	11.4	5
245	2017 ATA guidelines on the management of thyroid dysfunctions in pregnancy: what do OB/GYNs need to know?. <i>Gynecological Endocrinology</i> , 2019, 35, 276-279.	1.7	5
246	Pooled analysis of bleeding profile, efficacy and safety of oral oestradiol valerate/dienogest in women aged 25 and under. <i>European Journal of Contraception and Reproductive Health Care</i> , 2020, 25, 98-105.	1.5	5
247	Pituitary and ovarian interleukin-1 content changes according to estrous cycle and acute stress exposure. <i>Gynecological Endocrinology</i> , 1994, 8, 259-264.	1.7	4
248	An individualized approach to the management of vaginal atrophy in Latin America. <i>Menopause</i> , 2019, 26, 919-928.	2.0	4
249	The heat is on. <i>Climacteric</i> , 2020, 23, S1-S2.	2.4	4
250	International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. <i>Climacteric</i> , 2021, 24, 533-550.	2.4	4
251	Long-Term Consequences of Menopause. <i>Endocrinology</i> , 2020, , 1-13.	0.1	4
252	Sexuality, pelvic floor/vaginal health and contraception at menopause. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2022, 81, 85-97.	2.8	4

#	ARTICLE	IF	CITATIONS
253	Perimenstrual Asthma in Adolescents: A Shared Condition in Pediatric and Gynecological Endocrinology. <i>Children</i> , 2022, 9, 233.	1.5	4
254	Pharmacotherapy for female sexual dysfunctions (FSDs): what is on the market and where is this field heading?. <i>Expert Opinion on Pharmacotherapy</i> , 2023, 24, 135-143.	1.8	4
255	Pituitary LH reserve suggests high risk of bulimia in amenorrheic women. <i>Psychoneuroendocrinology</i> , 2001, 26, 721-730.	2.7	3
256	Clinical Study on the Dose-Effect Relationship of a Nifuratel-Nystatin Combination in the Treatment of Vulvo-vaginal Infections. <i>Arzneimittelforschung</i> , 2003, 53, 730-737.	0.4	3
257	Recovering sex drive in women – progress and opportunities. <i>Nature Reviews Urology</i> , 2016, 13, 67-68.	3.8	3
258	Clarifying vaginal atrophy’s impact On SEx and Relationships (CLOSER) survey in South Africa. <i>Climacteric</i> , 2017, 20, 49-54.	2.4	3
259	Macro-regional variation in attitudes toward and experiences of vulvar and vaginal atrophy among Italian post-menopausal women: a <i>post hoc</i> analysis of REVIVE survey data. <i>Gynecological Endocrinology</i> , 2017, 33, 389-394.	1.7	3
260	Has flibanserin revolutionized the treatment of hypoactive sexual desire disorder or is there still room for more effective therapeutics?. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 421-423.	1.8	3
261	Easy tools to screen Italian women suffering from migraine with and without aura in early reproductive age. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2019, 242, 63-67.	1.1	3
262	“50 Shades of sex” under hormonal contraception. <i>Gynecological Endocrinology</i> , 2020, 36, 753-754.	1.7	3
263	Prolactin as a neuroendocrine clue in sexual function of women across the reproductive life cycle: an expert point of view. <i>Gynecological Endocrinology</i> , 2021, 37, 490-496.	1.7	3
264	Expression and neuropeptidergic characterization of estrogen receptors (ER α and ER β) throughout the rat brain: Anatomical evidence of distinct roles of each subtype. , 1998, 36, 357.		3
265	Missed opportunities in contraceptive counselling: findings from a European survey-based study with simulated patient consultation. <i>European Journal of Contraception and Reproductive Health Care</i> , 2022, 27, 85-94.	1.5	3
266	Biallelic mutations in PSMC3IP are associated with secondary amenorrhea: expanding the spectrum of premature ovarian insufficiency. <i>Journal of Assisted Reproduction and Genetics</i> , 2022, 39, 1177-1181.	2.5	3
267	Ritanserin in Menstrual Migraine and Premenstrual Complaints Prophylaxis. <i>Cephalalgia</i> , 1991, 11, 195-196.	3.9	2
268	Ontogeny of the circadian rhythm in medial basal hypothalamic γ -endorphin content in female rat. <i>Journal of Endocrinological Investigation</i> , 1994, 17, 697-701.	3.3	2
269	Local estrogens for quality of life and sexuality in postmenopausal women with cardiovascular disease. <i>Climacteric</i> , 2009, 12, 112-116.	2.4	2
270	Hypoactive sexual desire disorder: can we treat it with drugs?. <i>Sexual and Relationship Therapy</i> , 2010, 25, 264-274.	1.2	2

#	ARTICLE	IF	CITATIONS
271	Impact of Chemotherapy and Hormone Therapy on Female Sexual Health. , 2011, , 525-534.		2
272	Cycle control with an extended-regimen oral contraceptive combining levonorgestrel and ethinyl estradiol that includes continuous low-dose ethinyl estradiol instead of the traditional hormone-free interval. International Journal of Women's Health, 2017, Volume 9, 739-747.	2.6	2
273	The effect of vulvovaginal atrophy on women's quality of life from an Italian cohort of the EVES study. Journal of Obstetrics and Gynaecology, 2020, 40, 512-519.	0.9	2
274	Myeloperoxidase and lactoferrin expression in semen fluid: Novel markers of male infertility risk?. Immunobiology, 2020, 225, 151999.	1.9	2
275	Vulvo-Vaginal Atrophy (VVA). , 2020, , 105-111.		2
276	Talking about genital problems with women aged over 70. Maturitas, 2020, 142, 73-74.	2.4	2
277	Vaginal Health: Insights, Views & Attitudes survey in Latin America (VIVA-LATAM): focus on Brazil. Climacteric, 2021, 24, 157-163.	2.4	2
278	Insulin resistance and potential modulators of ovarian reserve in young reproductive-aged women with obesity and type 1 diabetes. Gynecological Endocrinology, 2021, 37, 823-830.	1.7	2
279	Sexual disorders in Parkinson's disease. Functional Neurology, 2001, 16, 283-8.	1.3	2
280	Crohn's Disease and Female Infertility: Can Nutrition Play a Supporting Role?. Nutrients, 2022, 14, 2423.	4.1	2
281	Post-menopausal changes and dementing illness: Ovarian steroids as the causal link?. Aging Clinical and Experimental Research, 1997, 9, 66-67.	2.9	1
282	Women's sexuality after menopause: What role for androgens?. Sexuality, Reproduction & Menopause, 2004, 2, 204-208.	1.0	1
283	Vulvo-vaginal atrophy. , 0, , 52-57.		1
284	Vulvovaginal atrophy of menopause and its impact on sexual function in an Italian clinical cohort of post-menopausal women. Journal of Obstetrics and Gynaecology, 2021, 41, 290-297.	0.9	1
285	Clinical features of migraine with onset prior to or during start of combined hormonal contraception: a prospective cohort study. Acta Neurologica Belgica, 2021, , 1.	1.1	1
286	Predictors of postmenopausal dyspareunia. Climacteric, 2012, 15, 636.	2.4	1
287	Aging female brain: is there a change of adaptive stress?. Aging Clinical and Experimental Research, 1997, 9, 64-65.	2.9	0
288	Pituitary-adrenal responses to dexamethasone and CRH administration in patients with untreated Parkinson's disease. Aging Clinical and Experimental Research, 1997, 9, 69-70.	2.9	0

#	ARTICLE	IF	CITATIONS
289	Headache is a risk factor for the onset of hypertension in pregnancy. American Journal of Obstetrics and Gynecology, 2005, 193, S178.	1.3	0
290	Explorative study on the use of omalizumab in patients suffering from interstitial cystitis/bladder pain syndrome. Urogynaecologia International Journal, 2012, 26, 8.	0.2	0
291	Clinical and histological findings in bladder pain syndrome/interstitial cystitis: The implication of time of symptoms. Journal of Clinical Urology, 2018, 11, 248-253.	0.1	0
292	Hormonally Related Headaches. ISGE Series, 2019, , 93-100.	0.2	0
293	Impact of postmenopausal vaginal discomfort on sex and relationships in Brazil: the CLOSER survey. Climacteric, 2021, 24, 1-7.	2.4	0
294	Quality of Life and Sexual Health. ISGE Series, 2021, , 93-103.	0.2	0
295	Long-Term Consequences of Menopause. Endocrinology, 2020, , 335-347.	0.1	0
296	Female sexual dysfunction is more than just a hormonal problem. Climacteric, 2011, 14, 693.	2.4	0
297	Profile of Brazilian climacteric women: results from the Brazilian Menopause Study. Climacteric, 0, , 1-7.	2.4	0